Jubilant Pharmova Q3 Results Review - Decent Margin Improvement; Topline Disappoints: Nirmal Bang
We have increased our price earning multiple to 15 as we are expecting the debt to come down due to Sofie stake sale and better-than-expected margins.
Jubilant Pharmova Q3 FY24 results: profit at 66.8Cr, Revenue increased by 8.03% YoY
Jubilant Pharmova Q3 FY24 results: Revenue increased by 8.03% YoY & profit at 66.8Cr
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2023, published on February 03, 2024 in MINT (English) and HINDUSTAN (Hindi). Jubilant Pharmova Ltd - 530019 - Completion Of USFDA Audit Of Solid Dosage Manufacturing Facility At Roorkee Plant
Completion of USFDA audit of Solid dosage manufacturing facility at Roorkee plant Q3FY24 Quarterly & 9MFY24 Result Announced for Jubilant Pharmova Ltd.
Pharmaceuticals company Jubilant Pharmova announced Q3FY24 & 9MFY24 results: Revenue and Income: - Total income for Q3FY24 increased by 10% YoY to Rs 1,713 crore. - EBITDA for Q3FY24 grew by 63% YoY to Rs 254 crore with EBITDA margin expansion of 490 basis points YoY. - The company reported a Profit After Tax (PAT) of Rs 66 crore in Q3FY24, showing a remarkable improvement compared to a PAT of (Rs 16 crore) in Q3FY23. - For 9MFY24, total income rose 8% YoY to Rs 4,999 crore. - EBITDA for 9MFY24 showed a 16% increase YoY, reaching Rs 684 crore with a 100 basis point margin expansion. Segment Performance: - Radiopharma revenue in Q3FY24 grew by 23% to Rs 752 crore and EBITDA increased significantly by 153% to Rs 161 crore. - Allergy Immunotherapy revenue for Q3FY24 saw a 9% increase to Rs 161 crore, with EBITDA rising by 16% to Rs 62 crore. - CDMO Sterile Injectables Q3FY24 revenue increased by 11% to Rs 303 crore, though EBITDA for Q3FY24 was affected by planned extended shutdowns, expected to improve in Q4. - CRDMO Q3FY24 revenue stood at Rs 252 crore, with EBITDA margins at 16% despite facing industry headwinds. - Generics segment Q3FY24 revenue was reported at Rs 199 crore with an improving EBITDA trend. Debt: - Total Gross Debt as of December 31, 2023, was reported at Rs 3,419 crore. showing a slight increase compared to Rs 3,410 crore. as of March 31, 2023. Key Priorities and Future Outlook: - Focus on leveraging the Radiopharma segment's stable and high-margin core portfolio for continuing leadership in North America. - Spotlight on Allergy Immunotherapy market share growth in the US through venom immunotherapy and expanding in non-US markets. - In CDMO Sterile Injectables, emphasis on executing a $370 million capacity expansion to support projected market growth. - In Generics, steps toward enhancing quality and engagement with the US FDA for Import Alert resolution at the Roorkee facility. - In CRDMO, the objective is to drive new customer acquisitions and invest in capabilities to improve productivity. - For Proprietary Novel Drugs, focus on progressing clinical trials for LSD1/HDAC6 inhibitors and capitalizing on strategic opportunities for non-dilutive funding. Sustainability Initiatives: - The company has entered into a power purchase agreement to meet 90% of its electricity demand from renewable sources for its facilities in Karnataka. Result PDF Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release alongwith presentations on financials Q3 2024 Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Change in Management
Re-appointment of Mr. Arvind Chokhany as Whole-time Director of the Company Jubilant Pharmova Ltd - 530019 - Unaudited Financial Results Q3 FY 2024 Alongwith Limited Review Report
Unaudited Financial Results Q3 FY 2024 alongwith Limited Review Report Jubilant Pharmova Ltd - 530019 - Disclosure Under Regulation 30 Read With Schedule III To The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Disposal Of Investment
Disclosure under Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Disposal of Investment